gdc
Lymphoma

Drugs for Lymphoma

Here are the drugs and financial support services available to patients receiving treatment for Lymphoma.
2021 Patient Guide to Cancer Support Services
Hodgkin Lymphoma

Adcetris (brentuximab vedotin)

Drug company: Seagen
855-473-2873

Adcetris is a CD30-directed antibody-drug conjugate used for the treatment of patients with several types of classical Hodgkin lymphoma, including untreated stage III or IV disease.

Seagen Secure offers 1 financial assistance program for patients using Adcetris:

SeaGen Secure Patient Assistance Program

Patients who are uninsured and meet certain financial criteria will be eligible to receive Adcetris at no cost. With this program, assistance begins with a temporary 3-month period.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma. Keytruda is also used for the treatment of pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma that has relapsed after 2 or more lines of therapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda for free. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for couples, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for medicines, may request that an exception be made, provided their household income is not above a set limit.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of adults with classical Hodgkin lymphoma that has relapsed or progressed after autologous stem-cell transplant and Bendeka, or after 3 or more lines of systemic therapy that included autologous transplant.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Non‑Hodgkin Lymphoma (NHL)

Adcetris (brentuximab vedotin)

Drug company: Seagen
855-473-2873

Adcetris is a CD30-directed antibody-drug conjugate used for the treatment of patients with several types of systemic anaplastic large-cell lymphoma, a form of non-Hodgkin lymphoma (NHL). Adcetris is also used for patients with other types of CD30-expressing untreated peripheral T-cell lymphomas (PTCL), alone or in combination with cyclophosphamide, doxorubicin, and prednisone; and for patients with primary cutaneous anaplastic large-cell lymphoma or CD30-expressing mycosis fungoides, after systemic therapy.

Seagen Secure offers 1 financial assistance program for patients who have been prescribed Adcetris:

Seagen Secure Patient Assistance Program

Patients who are uninsured and meet certain financial criteria will be eligible to receive Adcetris at no cost. With this program, assistance begins with a temporary 3-month period.

Beleodaq (belinostat) for Injection

Drug company: Acrotech Biopharma
888-537-8277

Beleodaq is a histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a type of NHL.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Beleodaq:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 for the first injection of Beleodaq and then $25 for each subsequent injection, with a maximum benefit of up to $10,000 annually.

STAR Patient Assistance Program

This program provides Beleodaq free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Bendeka (bendamustine HCl) Injection

Drug company: Teva
888-587-3263

Bendeka is an alkylating drug used for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or after 6 months of Rituxan therapy.

Teva offers 1 financial assistance program for patients using Bendeka:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free. The financial criteria specify that the patient’s annual income must not exceed $60,700 for 1 person, $82,300 for 2 people, $103,900 for 3 people, $125,000 for 4 people, or $147,100 for 5 people.

Folotyn (pralatrexate)

Drug company: Acrotech Biopharma
888-537-8277

Folotyn is a folate analog metabolic inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Folotyn:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 out of pocket for the first injection of Folotyn and then $25 for each subsequent injection, with a benefit of up to $10,000 per calendar year.

STAR Patient Assistance Program

This program provides Folotyn free of charge to enrolled patients who meet the income, insurance, and residency eligibility requirements.

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of patients with Waldenström’s macroglobulinemia, a type of NHL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Mozobil (plerixafor)

Drug company: Sanofi Genzyme
833-930-2273

Mozobil is a hematopoietic stem-cell mobilizer used, in combination with granulocyte colony-stimulating factor, for the treatment of patients with non-Hodgkin lymphoma.

Sanofi Genzyme CareASSIST offers 1 financial assistance program for patients who are prescribed Mozobil:

CareASSIST Patient Assistance Programn

Through this program, patients who are uninsured or do not have coverage for Mozobil may be eligible to receive their medication at no cost. To be eligible, the patient’s annual household income must not be more than $100,000, or 500% of the federal poverty level. Patients enrolled in Medicare Part B who have no supplemental insurance may also be eligible to receive Mozobil through this program.

Poteligeo (mogamulizumab-kpkc)

Drug company: Kyowa Kirin
833-552-2737

Poteligeo is a CCR4-directed monoclonal antibody used for the treatment of adults who have relapsed or refractory mycosis fungoides, a type of non-Hodgkin lymphoma (NHL), and for patients with Sézary syndrome (cutaneous T-cell lymphoma), a rare type of NHL, after at least 1 systemic therapy.

Kyowa Kirin Cares offers 2 financial assistance programs for patients who have been prescribed Poteligeo:

Kyowa Kirin Cares Co-Pay Assistance Program

Patients with private insurance may be eligible to receive copay assistance for their Poteligeo prescription.

Kyowa Kirin Cares Patient Assistance Program

Uninsured patients whose annual gross income is less than or equal to 400% of the federal poverty level may be eligible to receive financial assistance for Poteligeo.

Rituxan (rituximab)

Drug company: Genentech
866-422-2377

Rituxan is a CD20-directed cytolytic antibody used for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-hodgkin lymphoma (NHL) as a single agent; first-line treatment of follicular, CD20-positive, B-cell NHL, in combination with first-line chemotherapy, and, in patients achieving a complete or partial response to a rituximab drug, in combination with chemotherapy, as single- agent maintenance therapy. Rituxan is also used for the treatment of non-progressing, low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line chemotherapy, and for first-line treatment of diffuse large B-cell, CD20- positive NHL, in combination with anthracycline-based chemotherapy regimens.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Truxima (rituximab-abbs)

Drug company: Teva
888-587-3263

Truxima, a biosimilar to Rituxan, is a CD20-directed cytolytic antibody used for the treatment of patients with relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent, or for patients with untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a response to Rituxan plus chemotherapy, as a single-agent maintenance therapy. Truxima is also used, alone, for patients with non-progressing (or stable), lowgrade, CD20-positive, B-cell NHL, after cyclophosphamide, vincristine, and prednisone chemotherapy.

Teva offers 2 financial assistance programs for patients who have been prescribed Truxima:

Truxima Patient Savings Program

Eligible patients with private insurance may pay as little as $0 for Truxima, with a maximum annual limit of $25,000. The program may cover eligible out-of-pocket costs incurred by the patient for Truxima within 90 days before program enrollment.

Teva Cares Foundation Patient Assistance Program

This program provides Truxima at no cost to patients who do not have insurance or whose insurance does not cover Truxima. Patients with health insurance must try other types of assistance before they can be approved for this program. Uninsured patients must meet certain financial requirements.

Valchlor (mechlorethamine)

Drug company: Helsinn
855-482-5245

Valchlor is an alkylating drug used for the topical treatment of stage IA or stage IB mycosis fungoides-type cutaneous T-cell lymphoma (a type of NHL), in patients who have received skin-directed therapy.

Helsinn offers 1 financial assistance program for patients who have been prescribed Valchlor:

Valchlor Co-pay Program

Eligible patients who have commercial health insurance whose copay or co-insurance is more than $10 per prescription of Valchlor will pay no more than $10 per prescription in out-of-pocket copay costs for Valchlor.

Yescarta (axicabtagene ciloleucel)

Drug company: Kite Pharma
844-454-5483

Yescarta is a CD19-directed genetically modified CAR T-cell immunotherapy used, after 2 or more lines of systemic therapies, for the treatment of adults with relapsed or refractory large B-cell lymphoma (a type of NHL), including primary mediastinal large B-cell lymphoma or high-grade B-cell lymphoma.

Kite Pharma offers 1 patient assistance program for patients who have been prescribed Yescarta:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Yescarta. (For more information, call 844-454-5483.)

Zolinza (vorinostat) Capsules

Drug company: Merck
800-727-5400

Zolinza is a histone deacetylase inhibitor used for the treatment of patients with cutaneous T-cell lymphoma (a type of NHL), that is progressive, persistent, or recurrent with or after 2 systemic therapies.

Merck offers 1 financial assistance program for patients who have been prescribed Zolinza:

Merck Patient Assistance Program

Uninsured patients who cannot afford to pay for Zolinza and have a household income of $51,040 or less for individuals, $68,960 or less for couples, or $104,800 or less for a family of 4, may qualify to receive their medication for free.

Diffuse Large B‑Cell Lymphoma (DLBCL) (a Type of NHL)

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of pediatric and adult patients with refractory primary mediastinal large B-cell lymphoma, or patients whose disease relapsed (returned) after 2 or more therapies.

Merck offers 2 financial assistance programs for patients who are prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for couples, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines, may request that an exception be made, provided their household income is not above a set limit.

Kymriah (tisagenlecleucel)

Drug company: Novartis
844-459-6742

Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of adults with relapsed or refractory large B-cell lymphoma (a type of NHL) after 2 or more systemic therapies, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, highgrade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients who have been prescribed Kymriah:

Kymriah Cares

This program offers financial assistance to eligible patients to help them access Kymriah. Patients must meet program eligibility criteria to qualify for support. Patients should work with their treatment center to submit a Service Request Form for Patient Support to Kymriah Cares.

Monjuvi (tafasitamab-cxix)

Drug Company: MorphoSys
855-421-6172

Monjuvi is a CD19-directed cytolytic antibody used, in combination with Revlimid, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from lowgrade lymphoma, in patients who are not eligible for autologous stem-cell transplant.

MorphoSys’s My Mission Support offers 2 financial assistance programs for patients who have been prescribed Monjuvi:

My Mission Support Copay Assistance Program

Through this program, eligible patients who have commercial or private insurance may be able to pay as little as $0 for Monjuvi, with a maximum annual benefit limit of $25,000.

MorphoSys Foundation Patient Assistance Program

Eligible patients who do not have insurance, or whose copay responsibility through their insurer presents a financial hardship, may be able to receive Monjuvi at no cost. The patient’s income must be less than $82,000 for an individual, or $170,000 for a family of 4.

Polivy (polatuzumab vedotin-piiq) for Injection

Drug Company: Genentech
866-422-2377

Polivy is a CD79b-directed antibody-drug conjugate used, in combination with Bendeka and Rituximab, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, after at least 2 previous therapies.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Polivy:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Polivy, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Polivy free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Polivy is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Drug Company: Genentech
866-422-2377

Rituxan Hycela is a combination of rituximab, a CD20- directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, used for the treatment of patients with untreated diffuse large B-cell lymphoma (DLCBL), in combination with chemotherapy with anthracycline-based chemotherapy regimens.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Yescarta (axicabtagene ciloleucel)

Drug company: Kite Pharma
844-454-5483

Yescarta is a CD19-directed genetically modified CAR T-cell immunotherapy used, after 2 or more lines of systemic therapies, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, or DLBCL arising from follicular lymphoma.

Kite Pharma offers 1 patient assistance program for patients using Yescarta:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Yescarta. (For more information call 844-454-5483.)

Follicular Lymphoma (a Type of NHL)

Aliqopa (copanlisib) for Injection

Drug company: Bayer
833-254-7672

Aliqopa is a kinase inhibitor used for the treatment of adult patients with relapsed follicular lymphoma who have received at least 2 systemic therapies.

Aliqopa Resource Connections offers 2 financial assistance programs for patients using Aliqopa:

Aliqopa $0 Co-Pay Program

This program allows patients with private insurance to pay $0 copay for Aliqopa, with a yearly savings of up to $25,000.

Aliqopa Resource Connections Patient Assistance Program

For eligible patients who are uninsured or underinsured, this program provides Aliqopa at no cost.

Copiktra (duvelisib)

Drug company: Verastem
833-570-2273

Copiktra is a dual PI3 kinase used for the treatment of adults with relapsed or refractory follicular lymphoma, after at least 2 systemic therapies.

Verastem Cares offers 3 financial assistance programs for patients who have been prescribed Copiktra:

Verastem Cares Co-Pay Assistance

Through this program, patients with private insurance may pay as little as $5 for their prescription of Copiktra, with a maximum annual benefit of $25,000 and no patient income requirement.

Verastem Cares Bridge Rx Program

This program will provide a free 14-day supply of Copiktra to patients with coverage delays or who have experienced loss of insurance lasting more than 5 days.

Verastem Cares Patient Assistance Program

Patients who are uninsured and have an annual income of $150,000 or less may qualify to receive Copiktra for free.

Gazyva (obinutuzumab)

Drug company: Genentech
866-422-2377

Gazyva is a CD20-directed cytolytic antibody used, in combination with bendamustine followed by Gazyva alone, for the treatment of patients with follicular lymphoma whose disease relapsed after, or is refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by Gazyva alone in patients achieving a partial remission, for adults with previously untreated advanced (stage II bulky, III, or IV) follicular lymphoma.

Genentech Oncology offers 2 financial assistance programs for patients using Gazyva:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gazyva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Gazyva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Revlimid (lenalidomide) Capsules

Drug Company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of patients with previously treated follicular lymphoma, in combination with Rituximab or a biosimilar to Rituximab.

Celgene Patient Support offers 3 financial assistance programs for patients who have been prescribed Revlimid:

Celgene Commercial Co-pay Program

This program reduces the cost of the copay for Revlimid to $25 or less for patients who have private insurance that does not cover the full cost of Revlimid.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients who have public insurance to outside resources that may help with the cost of copays, deductibles, and co-insurance.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Drug Company: Genentech
866-422-2377

Rituxan Hycela is a combination of rituximab, a CD20- directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, used for the treatment of patients with relapsed or refractory follicular lymphoma as a single agent; for patients with untreated follicular lymphoma, in combination with first-line chemotherapy; and for patients achieving a complete or partial response to rituximab and chemotherapy, as a single-drug maintenance therapy. Rituxan Hycela is also used, as a single medication, for the treatment of patients with non-progressing or stable follicular lymphoma after first-line chemotherapy with cyclophosphamide, vincristine, and prednisone.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription fill occurred within 180 days prior to enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Tazverik (tazemetostat) Tablets

Drug Company: Epizyme
833-437-4669

Tazverik is a methyltransferase inhibitor used for the treatment of adults with relapsed or refractory follicular lymphoma and EZH2 mutation, as detected by an FDAapproved test, after at least 2 previous systemic therapies. Tazverik is also used for adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

Epizyme offers 4 financial assistance programs for patients who are prescribed Tazverik:

Co-Pay Assistance Program

With this program, eligible patients who have private insurance will receive copayment assistance to reduce their outof- pocket costs of Tazverik.

Patient Assistance Program

Patients who meet this program’s financial requirements and are uninsured or underinsured may be eligible to receive Tazverik for free for the remainder of the calendar year through this program.

Bridge Supply Program

This program provides an emergency supply of Tazverik for free to eligible patients who have an unexpected disruption in their prescription drug coverage or supply.

QuickStart Program

Eligible patients may be able to receive Tazverik right away if they have a delay of more than 5 days in the authorization of their prescription drug coverage and if their doctor has determined they have to start medical treatment immediately.

Zevalin (ibritumomab tiuxetan)

Drug company: Acrotech Biopharma
888-537-8277

Zevalin is a CD20-directed radiotherapeutic antibody used for the treatment of patients with relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin lymphoma, or patients with untreated follicular lymphoma who achieve a partial or complete response to first-line chemotherapy.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Zevalin:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 out of pocket for the first injection of Zevalin and then $25 for each subsequent injection, with a benefit of up to $10,000 per calendar year.

STAR Patient Assistance Program

This program provides Zevalin free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Zydelig (idelalisib) Tablets

Drug company: Gilead
844-622-2377

Zydelig is a kinase inhibitor used for the treatment of patients with follicular B-cell non-Hodgkin lymphoma.

Zydelig AccessConnect offers 2 financial assistance programs for patients using Zydelig:

Zydelig AccessConnect Copay Coupon Card

Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or those who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or those who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Mantle‑Cell Lymphoma (a Type of NHL)

Brukinsa (zanubrutinib)

Drug company: BeiGene
833-234-4363

Brukinsa is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma after at least 1 previous therapy.

BeiGene offers 3 financial assistance programs for patients who are prescribed Brukinsa:

BeiGene Co-pay Assistance

Eligible patients who have private insurance will have $0 out-of-pocket costs for Brukinsa, up to a maximum of $25,000 per year.

BeiGene Bridge Supply Program

For eligible patients who have private insurance and are experiencing a coverage delay lasting more than 5 days, this program provides a 15-day supply of Brukinsa.

BeiGene Free Product Assistance

This program provides Brukinsa for free for patients who have no insurance or insufficient insurance. This program has certain financial and eligibility requirements.

Calquence (acalabrutinib) Capsules

Drug company: AstraZeneca
844-275-2360

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Calquence:

CALQUENCE Co-pay Savings Program

Eligible patients who have private insurance will pay $0 per month and may have access to up to $26,000 annually to assist with the out-of-pocket prescription costs associated with Calquence.

AZ&Me Prescription Savings Program

This program offers free medication from AstraZeneca to qualifying patients without insurance those in Medicare Part D, and those who receive their medication through participating healthcare facilities.

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of adults with mantle-cell lymphoma, after at least 1 previous therapy.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.

Revlimid (lenalidomide) Capsules

Drug company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of patients with mantle-cell lymphoma whose disease has relapsed or progressed after 2 therapies, one of which was bortezomib.

Celgene Patient Support offers 3 financial assistance programs for patients using Revlimid:

Celgene Commercial Co-pay Program

This program reduces the copay for Revlimid to $25 or less for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and co-insurance.

Tecartus (brexucabtagene autoleucel)

Drug company: Kite Pharma
844-454-5483

Tecartus is a CAR T-cell therapy (gene therapy) used for the treatment of adults with relapsed or refractory mantle-cell lymphoma.

Kite Pharma offers 1 financial assistance program for patients who have been prescribed Tecartus:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Tecartus. (For more information, call 844-454-5483.)

Velcade (bortezomib) for Injection

Drug company: Takeda Oncology
844-817-6468

Velcade is a proteasome inhibitor used for the treatment of patients with mantle-cell lymphoma.

Takeda Oncology offers 2 financial assistance programs for patients using Velcade:

Velcade Reimbursement Assistance Program

For patients with Medicare, Medicaid, or private insurance, this program will help find supplemental coverage if needed and provide assistance with copays.

Velcade Patient Assistance Program

Patients without insurance coverage may qualify to receive Velcade free of charge through this program. Patient eligibility is based on household income, treatment setting, and medically appropriate need.

Marginal‑Zone Lymphoma (a Type of NHL)

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of marginal-zone lymphoma, a type of non-Hodgkin lymphoma, in patients who require systemic therapy and have received at least 1 previous anti-CD20-based therapy.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are either uninsured, underinsured, or enrolled in Medicare Part D.

Revlimid (lenalidomide) Capsules

Drug company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of patients with marginal-zone lymphoma.

Celgene Patient Support offers 3 financial assistance programs for patients who have been prescribed Revlimid:

Celgene Commercial Co-pay Program

This program reduces the cost of the copay for Revlimid to $25 or less for patients who have private insurance.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients who have public insurance to outside resources that may help with the cost of copays, deductibles, and co-insurance.

Small Lymphocytic Lymphoma (SLL)

Calquence (acalabrutinib) Capsules

Drug company: AstraZeneca
844-275-2360

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with small lymphocytic lymphoma.

AstraZeneca 360 offers 2 financial assistance programs for patients who have been prescribed Calquence:

CALQUENCE Co-pay Savings Program

Eligible patients who have private insurance will pay $0 per month and may receive up to a $26,000 benefit per year to assist with the out-of-pocket prescription costs for Calquence.

AZ&Me Prescription Savings Program

This program offers free medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medication through participating healthcare facilities.

Copiktra (duvelisib)

Drug company: Verastem
833-570-2273

Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory small lymphocytic lymphoma, after at least 2 other therapies.

Verastem Cares offers 3 financial assistance programs for patients who have been prescribed Copiktra:

Verastem Cares Co-Pay Assistance

Patients who have private insurance may pay as little as $5 for their prescription of Copiktra, with a maximum annual benefit of $25,000 and no patient income requirement.

Verastem Cares Bridge Rx Program

This program provides a free 14-day supply of Copiktra to eligible patients who experience coverage delays or loss of insurance of longer than 5 days.

Verastem Cares Patient Assistance Program

Patients who are uninsured and have an annual income of $150,000 or less may qualify to receive Copiktra for free.

Gazyva (obinutuzumab)

Drug company: Genentech
866-422-2377

Gazyva is a CD20-directed cytolytic antibody used, in combination with Imbruvica or with Venclexta, for the first-line treatment of patients with small lymphocytic lymphoma.

Genentech Oncology offers 2 financial assistance programs for patients using Gazyva:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gazyva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Access to Care Foundation

This foundation provides Gazyva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a Bruton tyrosine kinase inhibitor used for the first-line treatment of patients with small lymphocytic lymphoma (SLL), with or without 17p deletion. Imbruvica is also used, in combination with Gazyva, for the first-line treatment of patients with SLL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients who have been prescribed Imbruvica:

You&i Instant Savings Program

Patients who have private insurance will pay no more than $10 per month for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Venclexta (venetoclax) Tablets

Drug company: AbbVie/Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used for the treatment of adults with small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least 1 previous therapy. Venclexta is also used, in combination with Gazyva or with rituximab, for the first-line treatment of patients with SLL.

AbbVie and Genentech offer 2 financial assistance programs for patients who have been prescribed Venclexta:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Venclexta, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Venclexta is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Zydelig (idelalisib) Tablets

Drug company: Gilead
844-622-2377

Zydelig is a kinase inhibitor used for the treatment of patients with small lymphocytic lymphoma after 2 or more systemic therapies.

Zydelig AccessConnect offers 2 financial assistance programs for patients using Zydelig:

Zydelig AccessConnect Copay Coupon Card

Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or those who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Table. Drugs Prescribed for Lymphoma

Hodgkin Lymphoma
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of adults with relapsed or refractory classical Hodgkin lymphoma

    Treatment of pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma that has relapsed after 2 or more lines of therapy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932
Non‑Hodgkin Lymphoma (NHL)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Adcetris (brentuximab vedotin)
  • Drug company
  • Seagen
  • Indication
  • Treatment of systemic anaplastic large-cell lymphoma or other CD30- expressing peripheral T-cell lymphomas, alone or in combination with cyclophosphamide, doxorubicin, and prednisone

    Treatment of primary cutaneous anaplastic large-cell lymphoma, or CD30-expressing mycosis fungoides, after systemic therapy
  • Patient support services
  • Seagen Secure Patient Assistance Program
    855-473-2873
    Drug name (generic name)
  • Beleodaq (belinostat) for Injection
  • Drug company
  • Acrotech Biopharma
  • Indication
  • Treatment of relapsed or refractory peripheral T-cell lymphoma (a type of NHL)
  • Patient support services
  • STAR Co-pay Assistance
    888-537-8277

    STAR Patient Assistance Program
    888-537-8277
    Drug name (generic name)
  • Bendeka (bendamustine HCl) Injection
  • Drug company
  • Teva
  • Indication
  • Treatment of indolent B-cell NHL progressing during or within 6 months of Rituxan treatment or Rituxan-containing regimen
  • Patient support services
  • Teva Cares Foundation Patient Assistance Program
    877-237-4881
    Drug name (generic name)
  • Mozobil (plerixafor)
  • Drug company
  • Sanofi Genzyme
  • Indication
  • NHL, in combination with granulocyte colony-stimulating factor
  • Patient support services
  • CareASSIST Patient Assistance Program
    833-930-2273
    Drug name (generic name)
  • Rituxan (rituximab)
  • Drug company
  • Genentech
  • Indication
  • Treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

    First-line treatment of follicular, CD20-positive, B-cell NHL, in combination with firstline chemotherapy, and, in patients achieving a complete or partial response to a rituximab drug, in combination with chemotherapy, as singleagent maintenance therapy

    Treatment of nonprogressing, low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line chemotherapy, and for first-line treatment of diffuse large B-cell, CD20-positive NHL, in combination with anthracycline-based chemotherapy regimens
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Truxima (rituximab-abbs)
    Drug company
  • Teva
  • Indication
  • Treatment of relapsed or refractory low-grade or follicular CD20-positive B-cell NHL

    Untreated follicular CD20- positive B-cell NHL, in combination with first-line chemotherapy

    Non-progressing, lowgrade, CD20-positive, B-cell NHL
  • Patient support services
  • Truxima Patient Savings Program
    888-587-3263

    Teva Cares Foundation Patient Assistance Program
    888-587-3263
    Drug name (generic name)
  • Valchlor (mechlorethamine)
  • Drug company
  • Helsinn
  • Indication
  • Treatment of stage IA/IB mycosis fungoidestype cutaneous T-cell lymphoma
  • Patient support services
  • Valchlor Co-pay Program
    855-482-5245
    Drug name (generic name)
  • Yescarta (axicabtagene ciloleucel)
  • Drug company
  • Kite Pharma
  • Indication
  • Relapsed or refractory primary mediastinal large B-cell lymphoma (a type of NHL), after at least 2 systemic therapies

    Relapsed or refractory high-grade B-cell lymphoma (a type of NHL), after at least 2 systemic therapies
  • Patient support services
  • Kite Konnect
    844-454-5483
    Drug name (generic name)
  • Zolinza (vorinostat) Capsles
  • Drug company
  • Merck
  • Indication
  • Cutaneous T-cell lymphoma (a type of NHL) that is progressive, persistent, or recurrent, with or after 2 systemic therapies
  • Patient support services
  • Merck Patient Assistance Program
    800-727-5400
Diffuse Large B‑Cell Lymphoma (DLBCL)/Primary Mediastinal LBCL
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of patients with refractory primary mediastinal large B-cell lymphoma, or patients whose disease relapsed after 2 therapies
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932
    Drug name (generic name)
  • Kymriah (tisagenlecleucel)
  • Drug company
  • Novartis
  • Indication
  • Treatment of relapsed or refractory large B-cell lymphoma after 2 systemic therapies, including DLBCL not specified

    High-grade B-cell lymphoma

    DLBCL arising from follicular lymphoma
  • Patient support services
  • Kymriah Cares
    844-459-6742
    Drug name (generic name)
  • Yescarta (axicabtagene ciloleucel)
  • Drug company
  • Kite Pharma
  • Indication
  • Treatment of relapsed or refractory large DLBCL not otherwise specified, after at least 2 systemic therapies

    Relapsed or refractory DLBCL arising from follicular lymphoma, after at least 2 systemic therapies
  • Patient support services
  • Kite Konnect
    844-454-5483
Follicular Lymphoma
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Gazyva (obinutuzumab)
  • Drug company
  • Genentech
  • Indication
  • Follicular lymphoma,in combination with bendamustine followed by Gazyva alone, in patients whose disease relapsed after, or is refractory to, a Rituxan-containing regimen

    Untreated advanced follicular lymphoma, in combination with chemotherapy followed by Gazyva alone, in patients achieving a partial remission
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Rituxan Hycela (rituximab/hyaluronidase human) Injection
  • Drug company
  • Genentech
  • Indication
  • Relapsed or refractory follicular lymphoma, as a single drug

    Untreated follicular lymphoma, in combination with first-line chemotherapy

    Maintenance therapy of follicular lymphoma, as a single drug, in patients with complete or partial response to rituximab plus chemotherapy

    Nonprogressing or stable follicular lymphoma, after first-line chemotherapy
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Tazverik (tazemetostat) Tablets
  • Drug company
  • Epizyme
  • Indication
  • Treatment of adults with relapsed or refractory follicular lymphoma and EZH2 mutation, as detected by an FDAapproved test, after at least 2 previous systemic therapies

    Treatment of adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options
  • Patient support services
  • Co-Pay Assistance Program
    833-437-4669

    Patient Assistance Program
    833-437-4669

    Bridge Supply Program
    833-437-4669

    QuickStart Program
    833-437-4669
Mantle‑Cell Lymphoma
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Tecartus (brexucabtagene autoleucel)
  • Drug company
  • Kite Pharma
  • Indication
  • Treatment of adults with relapsed or refractory mantle-cell lymphoma
  • Patient support services
  • Kite Konnect
    844-454-5483
Marginal‑Zone Lymphoma
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
Small Lymphocytic Lymphoma (SLL)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma. Ukoniq is used for MZL after 1 or more anti-CD20 therapies, and for follicular lymphoma after 3 or more lines of systemic therapy. Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
LymphomaBiomarkersFDA Approvals, News & Updates
FDA Approved Xalkori for Young Patients with Anaplastic Large-Cell Lymphoma and ALK Mutation
In January 2021, the FDA approved a new indication for Xalkori (crizotinib), an oral ALK inhibitor, for the treatment of young patients who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma and ALK mutation. Xalkori was previously approved for metastatic lung cancer and ALK or ROS1 mutation.
Last modified: April 8, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country